SFM
VIR icon

Sphera Funds Management’s Vir Biotechnology VIR Stock Holding History

Sphera Funds Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-90,855
Closed -$589K – 132
2025
Q1 		$589K Sell
90,855
-490,974
-84% -$4.37M 0.14% 101
2024
Q4 		$4.27M Buy
581,829
+488,500
+523% +$3.85M 0.77% 48
2024
Q3 		$699K Sell
93,329
-68,722
-42% -$597K 0.11% 103
2024
Q2 		$1.44M Buy
+162,051
New +$1.55M 0.2% 96

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sphera Funds Management's VIR Position: Q2 2025 in Review

Sphera Funds Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 90,855 shares — an estimated $589K sold.

Sphera Funds Management first reported a position in VIR in Q2 2024 and held it in 4 quarters. The position peaked at $4.27M in Q4 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Sphera Funds Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Sphera Funds Management sold 90,855 Vir Biotechnology shares in Q2 2025, an estimated $589K.
  • Sphera Funds Management first reported a position in Vir Biotechnology in Q2 2024 and held it in 4 quarters.
  • Sphera Funds Management's Vir Biotechnology position peaked at $4.27M in Q4 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.